Kesler Norman & Wride LLC purchased a new position in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 1,843 shares of the company's stock, valued at approximately $553,000.
A number of other institutional investors also recently modified their holdings of the stock. Whipplewood Advisors LLC bought a new stake in HCA Healthcare during the 4th quarter valued at $31,000. Tidemark LLC bought a new position in HCA Healthcare during the fourth quarter valued at about $36,000. Legacy Investment Solutions LLC purchased a new position in HCA Healthcare in the third quarter valued at approximately $39,000. Activest Wealth Management grew its stake in HCA Healthcare by 1,250.0% in the 4th quarter. Activest Wealth Management now owns 135 shares of the company's stock valued at $40,000 after buying an additional 125 shares in the last quarter. Finally, Pinnacle Bancorp Inc. boosted its holdings in HCA Healthcare by 50.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 150 shares of the company's stock valued at $45,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 62.73% of the company's stock.
HCA Healthcare Price Performance
HCA traded down $3.56 during trading hours on Monday, hitting $328.09. The company's stock had a trading volume of 814,269 shares, compared to its average volume of 1,362,423. The business's 50-day moving average price is $327.23 and its 200-day moving average price is $339.04. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $417.14. The stock has a market cap of $80.78 billion, a price-to-earnings ratio of 14.85, a P/E/G ratio of 1.10 and a beta of 1.48.
HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings data on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, topping analysts' consensus estimates of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same period last year, the company posted $5.90 EPS. Sell-side analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.
HCA Healthcare Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 17th were given a dividend of $0.72 per share. The ex-dividend date was Monday, March 17th. This represents a $2.88 dividend on an annualized basis and a yield of 0.88%. This is an increase from HCA Healthcare's previous quarterly dividend of $0.66. HCA Healthcare's dividend payout ratio (DPR) is presently 13.11%.
Insider Buying and Selling
In other HCA Healthcare news, SVP Jennifer Berres sold 9,533 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $322.59, for a total value of $3,075,250.47. Following the completion of the transaction, the senior vice president now directly owns 15,412 shares of the company's stock, valued at approximately $4,971,757.08. The trade was a 38.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on HCA. Bank of America dropped their target price on HCA Healthcare from $380.00 to $370.00 and set a "buy" rating for the company in a research report on Monday, January 27th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $380.00 price objective on shares of HCA Healthcare in a report on Tuesday, December 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $405.00 target price on shares of HCA Healthcare in a report on Monday, January 27th. KeyCorp decreased their price objective on shares of HCA Healthcare from $420.00 to $370.00 and set an "overweight" rating for the company in a report on Tuesday, January 7th. Finally, Truist Financial reduced their price objective on HCA Healthcare from $430.00 to $390.00 and set a "buy" rating for the company in a report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, HCA Healthcare presently has an average rating of "Moderate Buy" and an average target price of $385.67.
View Our Latest Analysis on HCA Healthcare
About HCA Healthcare
(
Free Report)
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Further Reading
Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
